MUC5AC and chronic obstructive pulmonary disease: A previous clinical trial evaluating chronic therapy (4 weeks) with an inhaled EGFR inhibitor (BIBW 2948) in stable COPD reported a dose-dependent inhibition of EGFR activation with an associated reduction in epithelial mucin stores at higher doses (49).